U.S. Electrical Stock News

Earlier in Q2 2026, Welltower reported strong Q1 results, with revenue rising about 40%, senior housing same-store NOI up sharply, and portfolio occupancy improving to roughly 89%, prompting management to raise full-year 2026 normalized FFO guidance while keeping its payout ratio under 50%. This combination of faster growth and a conservative payout suggests management sees room to support dividends while continuing to invest across its healthcare real estate platform. We’ll now explore how...

First quarter earnings shift draws fresh attention to Protagonist Therapeutics Protagonist Therapeutics (PTGX) has moved from a loss to a profit in the first quarter of 2026, reporting net income of US$3.78 million after a net loss of US$11.66 million a year earlier. See our latest analysis for Protagonist Therapeutics. The earnings swing to profit comes after a strong run for investors, with the share price delivering a 25.39% return over the past 90 days and a very large 292.25% total...

Oracle (ORCL) is back in focus after a series of AI and cloud announcements, including defense contracts for classified environments, strong Q3 FY2026 revenue and backlog figures, and fresh customer wins with Ishan Technologies and Samsung. See our latest analysis for Oracle. Those AI and cloud headlines are arriving after a sharp run, with Oracle’s share price gaining 13.63% over the past month and 20.49% over 90 days, while its 1-year total shareholder return of 21.43% and 5-year total...

In early May 2026, BioCryst Pharmaceuticals reported first-quarter revenue of US$156.41 million but a net loss of US$721.81 million, while maintaining full-year 2026 revenue guidance of US$635 million to US$660 million and announcing a European licensing deal for navenibart that includes a US$70 million upfront payment plus potential milestones and royalties. The navenibart agreement with Neopharmed Gentili’s Irish affiliate both brings immediate capital to BioCryst and outsources European...

Biogen (NasdaqGS:BIIB) is advancing its experimental Alzheimer’s drug diranersen into late stage trials after Phase 2 CELIA data. The therapy, an antisense oligonucleotide that targets tau protein, did not meet the study’s primary endpoint but showed strong biomarker changes and signs of cognitive benefit. The decision extends Biogen’s Alzheimer’s efforts beyond amyloid focused treatments and increases attention on its neurology pipeline. For you as an investor, this keeps Biogen in the...

Magnolia Oil & Gas Corporation ( NYSE:MGY ) shareholders will have a reason to smile today, with the analysts making...

Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...

Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...

The latest analyst coverage could presage a bad day for Arcus Biosciences, Inc. ( NYSE:RCUS ), with the analysts making...

MSA Safety stock snapshot after recent moves MSA Safety (MSA) has drawn fresh attention after recent price swings, with the stock closing at US$171.24. For investors, the question now is how current valuation aligns with fundamentals. See our latest analysis for MSA Safety. Recent trading has been choppy, with the share price falling 15.2% over the past 90 days but still showing a 5.55% year to date share price return and 8.68% one year total shareholder return. This suggests moderating...

Genco Shipping & Trading (NYSE:GNK) has rejected an unsolicited tender offer from Diana Shipping Inc. The board voted unanimously against the bid and is urging shareholders not to tender their shares. The rejection comes during an active takeover and proxy contest focused on control, valuation, and governance. For investors watching NYSE:GNK, this board level pushback follows a strong run in the stock, with shares up 33.6% year to date and 82.7% over the past year, closing at $24.63. The...

In recent commentary, Applied Industrial Technologies has been flagged for underperformance in its core business, with organic revenue and earnings growth over the past two years trailing industry peers and highlighting a heavier dependence on acquisitions to sustain expansion. This weaker internal growth profile, combined with only modestly projected sales improvement, raises questions about how effectively Applied can balance acquisition-driven growth with the health of its underlying...

If you are wondering whether Roku at around US$124.02 is still priced fairly after its recent run, you are not alone in questioning what the current share price really reflects. The stock has pulled back about 4.3% over the last week, although it is still up 13.4% over the past month, 14.1% year to date, and 73.8% over the last year. The 3 year return sits at 135.7% and the 5 year return shows a decline of 62.5%. Recent headlines around Roku have focused on its positioning in streaming, its...

Earlier this month, Hormel Foods Corporation launched the SPAM® Dog, a SPAM-based hot dog for foodservice operators, rolling out across restaurants, stadiums, and convenience stores after its national debut at the National Restaurant Association Show in Chicago. This reimagined SPAM format highlights Hormel’s push to refresh core brands through convenience-ready, branded, value-added products aimed at higher-margin foodservice channels. We’ll now explore how this SPAM® Dog expansion into...

Hilltop Holdings: Recent Performance Snapshot Hilltop Holdings (HTH) has been trading around its recent close of US$36.29, with the stock down about 2% over the past month and roughly 8% over the past 3 months. Despite this pullback, the stock shows a total return of about 20% over the past year and around 25% over the past 3 years, with year-to-date performance near 7%. See our latest analysis for Hilltop Holdings. Recent share price weakness, with the 90 day share price return down 7.6%,...

In the past quarter, 10x Genomics, Inc. reported first‑quarter 2026 revenue of US$150.84 million, down from US$154.88 million a year earlier, while reducing its net loss to US$13.47 million and basic loss per share to US$0.10. The results, which combined a slight sales decline with a meaningfully smaller loss, have sharpened attention on how the company balances growth investments with funding and pricing pressures in the research market. Against this backdrop of lower revenue but improved...

Wondering whether Stanley Black & Decker stock at around US$75 is giving you value or asking too much? Price is only half the story; the real question is what you are getting for it. Over the last month the share price has risen 11.8%, yet it is still down 1.7% year to date and up 10.2% over the past year, which can leave the stock looking very different depending on your time frame. Recent coverage has focused on how the stock's multi year performance, including a 3 year return of 3.8% and...

U.S. Supreme Court rules that freight brokers can be held liable for damages in trucking incidents. Ruling is seen as supportive of J.B. Hunt Transport Services' vertically integrated trucking and logistics model. Decision may increase legal and compliance risks for asset light brokers that do not operate their own fleets. J.B. Hunt Transport Services, listed as NasdaqGS:JBHT, sits in a different position from many freight brokers because it combines trucking assets with logistics...

NVIDIA (NVDA) continues to draw attention after recent share price swings, with the stock down about 4.4% over the past day but higher over the past week, month and past 3 months. See our latest analysis for NVIDIA. That 4.4% one day drop sits against a stronger backdrop, with a 7 day share price return of 4.7%, a 30 day return of 13.3% and a year to date gain of 19.31%. The 1 year total shareholder return of 66.45% and very large 5 year total shareholder return suggest longer term momentum...

It's been a pretty great week for Shoulder Innovations, Inc. ( NYSE:SI ) shareholders, with its shares surging 18% to...

Nexa Resources (NEXA) has drawn investor attention after recent trading, with the stock closing at US$14.85 and showing mixed short term performance, including a 1 day decline and gains over the past 3 months and year. See our latest analysis for Nexa Resources. That latest dip in the share price sits against a much stronger backdrop, with the stock posting a 90 day share price return of 24.48% and a 1 year total shareholder return of 191.56%. This suggests momentum has been building rather...

Earlier this week, CMS Energy Corporation approved amendments at its May 8, 2026 annual meeting and launched a US$3.00 billion at-the-market common equity program, while shareholders rejected a proposal to allow action by written consent. This combination of expanded authorized shares, new equity issuance capacity and preserved limits on shareholder-initiated actions materially reshapes CMS Energy’s governance and capital structure flexibility. We’ll now examine how CMS Energy’s new US$3.00...

Henry Schein (HSIC) stock is in focus after first quarter results highlighted steady U.S. dental and technology performance, reaffirmed full year guidance, and an industry report that places clinical execution, not scale, at the center of practice growth. See our latest analysis for Henry Schein. Henry Schein’s recent Q1 update, reaffirmed 2026 outlook and ongoing buybacks have supported sentiment. However, the stock’s 30 day share price return is down 6.07% and its 1 year total shareholder...

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, its Smart GLP-1 gene therapy candidate for type 2 diabetes. An important detail for investors is that this regulatory clearance makes Fractyl a dual clinical-stage company, advancing both its Revita procedure for post‑GLP‑1 weight maintenance and its Rejuva gene therapy platform...